List of Therapeutic Companies in Colorado - 42

Ajna BioSciences is pioneering the development of FDA-approved botanical pharmaceuticals to revolutionize the world of medicine. Our strategy encompasses a focus on select plant and fungi species with a well- established history of therapeutic use, which streamlines the drug discovery process, mitigates late-stage clinical trial risk, and propels us towards unprecedented medicinal breakthroughs. With a specialized infrastructure and industry expertise, we're strategically poised to lead and create significant value in this exciting, nascent category of pharmaceuticals. Join us as we tap into the transformative potential of nature, shaping the future of health and medicine.

Allander biotechnologies is a biotech company at the R&D stage focusing on drug development for unmet medical needs in tissue regeneration.

Ambrosia Biosciences Inc. is a privately held drug discovery company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders.

Our mission is to decrease the quantity and severity of infections that cause human suffering through the creation and development of novel, targeted, antimicrobial therapies. Our lead technology, Veriox®, is a first-of-it's-kind, proprietary peracid/hydrogen peroxide based non-systemic antimicrobial agent. Our vision is to improve societal health by protecting humans, animals and the environment from harmful viruses and chemical agents. ArmiClenz™ (EPA registered disinfectant spray, cleaner/odor control) and ArmiVet™ (Topical wound, rash and hot spot care for animals) are two exciting new consumer brands that support our vision.

Arthroventions™ is improving the quality of life for patients with joint disease by developing technologies that enable more effective joint care. Over 70 million Americans (1 in 5) have a form of joint disease. It impacts more people than cancer, there is no cure, and the longer and more active a lifestyle, we live the more likely we will experience it. At Arthroventions, we believe the synovial fluid is the key to diagnosing and treating the different types of joint disease, including Osteoarthritis and Rheumatoid Arthritis. Unlike other chronic diseases, such as cancer, there are no diagnostics assays that can differentiate between disease phenotypes or to predict drug responsiveness. This results in patients receiving ineffective treatments based on physician and payer preference. Our first product line is a Class I medical device that facilitates the aspiration/removal of synovial fluid from and the injection of therapeutics into the joint space, which it is estimated that 30% of these procedures miss the joint space. Our new approach reduces patient pain and decreases the probability of missing the joint space, thereby improving the delivery of therapeutics and patient comfort. Using our devices, physicians and providers can realize additional revenue with improved quality of care. Our products support all types of intra-articular injections, including corticosteroids, viscosupplementation, and new regenerative therapy products such as Platelet Rich Plasma (PRP), Bone Marrow Aspirate Concentrate (BMAC), and Adipose derived cells. Join us and take the first step towards more effective joint care.

BioLoomics is a preclinical stage biotechnology company leveraging directed evolution of antibodies in human cells to create ADCs with improved internalization and trafficking. Our proprietary tech combines single-cell bioassay engineering, robotics, and ML.

Bolder BioTechnology has a diversified pipeline of proprietary, long-acting human protein pharmaceuticals that include potential treatments for hematological and endocrine disorders, cancer supportive care, and orphan genetic diseases.

Cerapedics is a global, commercial-stage orthopedics company that aspires to redefine the standard of care for bone repair by healing bones faster and at higher rates, without compromising safety, so that patients can live their healthiest lives. Bone grafts, including Cerapedics’ products, are used in over four million annual spine, orthopedics, trauma and interventional procedures world-wide. Cerapedics’ product, i-FACTOR®, is FDA approved for single-level cervical spinal fusions in the United States. Cerapedics’ next-generation product is currently being evaluated for use in lumbar interbody fusion through ASPIRE, a pivotal IDE study, and has been granted a Breakthrough Device Designation by the FDA. Cerapedics is headquartered in Westminster, CO.

Cime has harnessed recent advancements in synthetic chemistry to develop a proprietary platform unique to the industry that is faster, more efficient, and more cost effective than current solutions By combining the synthesis and screening stages of drug discovery, we significantly accelerate the Design-Make-Test-Analyze paradigm.

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.

Enliven Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer live not only longer, but better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall patient well-being. Enliven’s discovery process combines deep insights from clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies.

Exxel Pharma is a pharmaceutical company focused on the development of innovative, small molecule based medicines for management of pain and treatment of neuronal hypersensitivity disorders.

Foresight Diagnostics is a precision medicine company developing a novel liquid biopsy test for the measurement of minimal residual disease (MRD) for aid in patient management that is funded by leading diagnostics VC firms in Silicon Valley. Foresight’s cell-free DNA testing platform was developed in the labs of two prominent professors at Stanford University and is backed by several major peer-reviewed publications. The company has garnered significant partnering interest from multiple pharmaceutical companies in oncology and is poised for rapid growth. Foresight Diagnostics is headquartered in Aurora, Colorado.

We are a Colorado-based biomaterials company intentionally designing new materials to improve wound healing. Our materials are anti-inflammatory, prevent bacterial adhesion, and are capable of controlled drug delivery.

GID Group’s SVF-2 device and therapy, pending FDA approval, gives providers and patients a major development in cellular medicine to help treat osteoarthritis pain and to delay or provide an alternative to total knee replacement surgery. GID’s technology harvests, isolate and reimplants the right type and combination of one’s own healing cells. Our first FDA-approved pivotal clinical study, a closely watched rigorous trial, had no serious adverse events and showed significant improvements in pain and function. The FDA has granted conditional approval for a second final pivotal clinical trial. Cellular therapy addresses an unmet need in 14 million people living with osteoarthritis of the knee, offering a less time consuming, painful and costly treatment for everyone that requires no joint surgery and no drugs for osteoarthritis pain. Help relieve the $200 billion burden of osteoarthritis management on our healthcare system. Heal intelligently.

Greffex™ is a privately held, multi-national company, headquartered in Aurora, Colorado. Established in 1999, Greffex has developed a novel genetic platform for the development and production of vaccines. Our proprietary GREVAX™ Universal Platform delivers vaccines in a faster, more affordable and more efficient manner. Once a pathogen has been identified, Greffex's team designs and produces a GREVAX™ vaccine in as little as 4 weeks. The state-of-the-art flexibility of the GREVAX™ Universal Platform makes it the ideal delivery vehicle for vaccines against a wide variety of infectious disease, including but not limited to Pandemic Influenza strains, Anthrax and Dengue Fever, as well as Malaria, Hepatitis C, Respiratory Syncytial Virus (RSV), Ebola, HPV, Plague, Tuberculosis and a host of other vaccine candidates.

Heska is now an Antech company. Through innovation, invention, and strategic partnerships with worldwide leaders in diagnostics and treatments, Heska provides the benefits of latest generation technologies to veterinary professionals. Heska's range of in-house lab diagnostic solutions include Chemistry, Hematology, Blood Gas & Electrolytes, Immunodiagnostics, Artificial Intelligence-guided Urine & Fecal, Digital Cytology, Heartworm testing, and more. Utilize the highest sensitivity allergy testing available with Heska's immunotherapy solutions. Heska's digital imaging lineup boasts the latest High-Definition Digital Radiography and Digital Ultrasound technologies, paired with Cloud Based data archival, management, and sharing services. Discover all the ways Heska can help provide a voice for your patients.

MBC Pharma, Inc. is a pharmaceutical company discovering and developing novel medicines for the treatment of oncology, bone and infectious diseases. MBC Pharma's patented technologies improve upon the benefit of known drugs by adding tissue targeting and increased cancer cell specificity and uptake.

MenoGeniX is a privately-held, clinical stage biopharmaceutical company, dedicated to researching and developing a novel potential treatment for women suffering from hot flashes and related vasomotor symptoms of menopause.

Metabiomics has developed a new type of microbiome diagnostic test for early detection and monitoring of polymicrobial and immunological diseases such as inflammatory bowel disease, colon cancer, HIV infection, alcoholic liver disease, and others that are non-invasive, lower cost, more sensitive and accurate than currently available diagnostic procedures. For the past 10 years, Metabiomics has been a pioneer in human microbiome research specializing in functional metagenomics and systems biology applied to advances in microbial DNA sequencing methods, clinical research, and in vitro diagnostics. Our on-going clinical research is unraveling some of the secret relationships between human microbial communities, immunology, and health. Our research collaborations with Diversigen, the Harvard Chan School of Medicine, Penn State University and George Mason University Microbiome Analysis Center and several medical research institutions are focusing on microbial biomarkers and immunological responses in intestinal dysbiosis, colon disease and cancer, liver disease, and other immunological diseases.

Neurexis is developing an optimized peptide with demonstrated efficacy and safety in small and large animal models of global cerebral ischemia.

Researchers and Developers of Cannabinoid-Based Pharmaceuticals in Accordance with U.S. Food and Drug Administration (FDA) Pre-Clinical and Clinical Pathways

Nexo Therapeutics is a small molecule oncology company dedicated to the discovery and development of new drugs for cancer patients who currently lack meaningful therapies. Nexo combines covalent ligand discovery and chemical biology with expertise in cancer biology and medicinal chemistry to target fundamental drivers of cancer by innovative approaches. With facilities in Golden, CO and Watertown, MA, Nexo is led by Founder and CEO, Andrew Phillips, PhD. For more information, please visit www.nexotx.com.

We're bringing something new to the table, delivering thoughtfully-constructed, affordable treatment that works. Our 14-week program combines talk therapy with best in class medication management, including ketamine, for difficult to treat depression, anxiety, and PTSD — because no one should have to live with debilitating mental health conditions that are actually treatable.

At OncoVerity, we're not just developing a new treatment—we're doing something truly unique and meaningful. We're establishing a disruptive model using cutting-edge technology to advance cancer therapies. Our mission is to quickly advance therapies that turn hope into reality for patients, their families, and caregivers.   One of the things that sets OncoVerity apart is our approach. We are knocking down traditional barriers between academia and industry by building a team that bridges both worlds. We believe that cutting-edge technology is essential, but it is only one piece of the puzzle.   The true power behind our vision lies in: The brilliance of our people: Your entrepreneurship, ingenuity, drive, and passion are what will fuel our success. The richness of our diversity: A variety of perspectives and backgrounds is essential for groundbreaking solutions. The strength of our collaboration: We are stronger together, and teamwork is at the heart of everything we do.

OnKure Therapeutics is a precision oncology company committed to the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancer.

Orbit Genomics is transforming complex disease diagnosis, treatment and prevention through early warning genomics. Our patent pending OrbiSeq™ platform analyzes novel genomic markers which uniquely reflect not only inherited predisposition to disease, but also risk acquired from lifestyle and environmental exposures. OrbiSeq can be applied to diagnose, treat and help prevent complex diseases including cancer, heart disease and neurological diseases. Our first product is an aid to diagnosis for lung cancer, the world’s deadliest cancer and the only major one without a routine screening test. Diagnosis often requires an expensive and invasive biopsy. Our simple blood test will eliminate unnecessary biopsies.

Origin Endoscopy was formed through a collaboration of inventors from Johns Hopkins Medicine and the University of Maryland, and commercial experts in the interventional endoscopy space. Their primary technology is designed to control and extend the hemostatic effects of gastrointestinal (GI) bleeding during a variety of endoscopy procedures.

PhotonPharma is an immuno-oncology company with a break-through technology that stimulates a patient's own immune system to seek out and destroy their cancer cells. We have a patent protected process that precisely inactivates DNA/RNA of a patient's own tumor cells while leaving the cells alive with all of unique tumor specific antigen targets (neoantigens) intact. The process is simple, fast and inexpensive. A patient's tumor cells can be extracted, inactivated and administered back on the same day. Efficacy and safety has been demonstrated in a dog trial (companion animals) and in mouse studies.

Respirogen's technology will provide oxygen independent from damaged lungs. Acute respiratory distress syndrome (ARDS) is an acute severe lung disease commonly encountered in intensive care units (ICU). It can be caused by several triggers, including pneumonia or trauma. It is characterized by widespread injury of the alveolar–capillary membrane, resulting in protein rich noncardiogenic pulmonary edema (fluid accumulation in the lungs) and acute respiratory failure (ARF). ARDS results in severe hypoxaemia, which is refractory to oxygen treatment and requires assisted ventilation.

Reven Pharmaceuticals is a privately-held clinical-stage biopharmaceutical company founded in 1999.

RheumaGen is the only cell and gene therapy company editing the HLA gene to cure autoimmune diseases at their source.

SeaStar Medical is a commercial-stage medical technology company based in Denver, Colorado, focused on developing extracorporeal therapies to combat excessive inflammation in critically ill patients. Incorporated in 2020, the company aims to improve patient outcomes by transforming immune responses or removing harmful cytokines that contribute to organ failure. The flagship product, the Selective Cytopheretic Device (SCD), is designed to neutralize overactive immune cells and halt cytokine storms, which can lead to severe hyperinflammation. SeaStar Medical also offers QUELIMMUNE (SCD-PED), the first FDA-approved treatment for life-threatening acute kidney injury in critically ill pediatric patients. The company has received Breakthrough Device Designation for multiple therapeutic indications, facilitating a faster approval process. Led by a team of experienced professionals, including critical care physicians, SeaStar Medical targets critical care clinicians and hospitals, providing innovative solutions for managing severe inflammatory conditions.

Delivering life changing & first-in-class therapies to patients suffering from debilitating diseases #Science #GeneTherapy #Biotechnology #Medicine #Innovation

Sudhin Biopharma Co. is a biotechnology company developing efficient continuous biological manufacturing processes for therapeutic biologicals, sweet proteins, cell therapies and biological roducts.

Tolmar is a Northern Colorado based pharmaceutical research, development, manufacturing and commercial operations company. Tolmar develops and manufactures both proprietary and generic pharmaceutical products with specific focus in dermatology, oncology, and specialty injectable therapeutic areas.

Developing investigational treatments to attack liver metastases and pancreatic solid tumors and stimulate the immune system by delivering a combination of immunotherapies directly to the site of disease.

For patients and doctors battling chronic resistant infections, Validus Cellular Therapeutics is developing VCT-101, a novel preclinical stage anti-infective therapy unlike current small molecule antibiotics which are susceptible to resistance and are limited accessing infections. VCT-101 is a cell therapy to be given with standard of care antibiotic regimens to successfully treat of chronic infections through direct bacterial killing and immune system boosting mechanisms.

Simplifying Cancer's Complexities. With the complexities of cancer care exploding due to the paradigm shift towards precision medicine, we saw a need for a platform that actively assists clinicians. We call this Halo Intelligence. Halo Intelligence is the first whole knowledge system that brings together everything clinicians need to find the right treatment plan for every patient, every time. It does this by distilling data from all aspects of the VieCure EcoSystem. The end result is a seamless marriage of artificial intelligence and the clinicians' own natural intelligence creating what we call, The Halo Effect. https://www.viecure.com/careers

Vivaldi Biosciences is developing vaccines for protection against epidemic and pandemic viral respiratory diseases using its Delta NS1 vector and innovative cell-based production technologies. Vivaldi’s DeltaFLU universal influenza vaccine is in Phase 2 clinical development. Its Delta-19 universal influenza/Covid-19 vaccine will enter clinical trials in 2021. Delta NS1 is a versatile and robust technology platform for self-adjuvanting vaccines administered by nasal spray. Delta NS1 is a replication-deficient vaccine vector based on a genetically modified, safely attenuated influenza virus strain. Delta NS1-based vaccines have the unique ability to rapidly induce interferon, generating protection against circulating viruses entering the nasal passages, and activating systemic antibody and cell-based protective immunity.

Vivos is a Massachusetts-based medical technology firm that researches and develops oral therapies for the treatment of dentofacial abnormalities, and sleep apnea disorders.